Immunexpress
PrivateLast Round
Grant
Jun 16, 2020
Total Funding Raised
$9.42M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Immunexpress operates in Healthcare & Life Sciences and is based in Seattle, Washington. Its latest recorded funding round was a Grant round in June 2020.
Immunexpress is a biotechnology company that develops and commercializes molecular diagnostic technologies designed for the early detection of sepsis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immunexpress Comparables
Compare Immunexpress with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ASEP Medical Holdings Inc. | 78% | |
| GenomeKey | 74% | |
| Inflammatix | 74% |
For institutional investors. Book with your work email.
Immunexpress Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 16, 2020 | ||||
| VC Round | Oct 3, 2019 | ||||
| Grant | Feb 6, 2019 | ||||
| Series A | Mar 5, 2014 | ||||
| Private Equity | Jun 19, 2012 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Immunexpress Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| U.S. Department of Health and Human Services | Grant |
| Public Health Emergency Medical Countermeasures Enterprise | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 236% MoM, reaching 1.5K.
- Jun 1, 2025
Monthly visitors grew 194% MoM, reaching 2.5K.
For institutional investors. Book with your work email.
Immunexpress Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Immunexpress's valuation, stock price, and market status.
Is Immunexpress a public or private company?
Immunexpress is a private company.
What is the current stock price of Immunexpress?
Immunexpress is a private company, so its shares have no public market price. Caplight tracks Immunexpress's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Immunexpress worth (valuation)?
Valuation information for Immunexpress is not publicly available.
Can I buy Immunexpress stock?
Immunexpress shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Immunexpress's last funding round?
Immunexpress's most recent funding round was Grant on June 16, 2020.
Who are the main investors in Immunexpress?
Key investors in Immunexpress include U.S. Department of Health and Human Services, Public Health Emergency Medical Countermeasures Enterprise.
Will Immunexpress IPO soon?
No public IPO plans have been announced for Immunexpress.
How can I track Immunexpress secondary market activity?
Caplight tracks bids, offers, and trades in Immunexpress's shares on secondary markets.